Combining Chemotherapeutic Agents, Targeted Therapies, Vaccines and Natural Bioactive Compounds for Mesothelioma: Advances and Perspectives

October 7, 2025 | Comments Off on Combining Chemotherapeutic Agents, Targeted Therapies, Vaccines and Natural Bioactive Compounds for Mesothelioma: Advances and Perspectives

Oncology Research 2025 August 28 [Link] Raffaele Carrano, Carlotta Zucca, Nicla Cristina, Martina Grande, Eleonora Leti Maggio, Riccardo Bei, Antonio Infante, Chiara Focaccetti, Valeria Lucarini, Loredana Cifaldi, Laura Masuelli, Luciano…

Perioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analyses

October 6, 2025 | Comments Off on Perioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analyses

Nature Medicine 2025 September 8 [Link] Joshua E Reuss, Paul K Lee, Reza J Mehran, Chen Hu, Suqi Ke, Amna Jamali, Mimi Najjar, Noushin Niknafs, Jaime Wehr, Ezgi Oner, Qiong…

MiR-193b-3p and miR-132-3p as prognostic biomarkers of survival in pleural mesothelioma patients treated with first-line bevacizumab plus pemetrexed-platinum chemotherapy in the IFCT-0701 MAPS phase 3 trial

October 3, 2025 | Comments Off on MiR-193b-3p and miR-132-3p as prognostic biomarkers of survival in pleural mesothelioma patients treated with first-line bevacizumab plus pemetrexed-platinum chemotherapy in the IFCT-0701 MAPS phase 3 trial

Translational Oncology 2025 November [Link] Guénaëlle Levallet, Christian Creveuil, Alexandre Léger-Vigot, Solenn Brosseau, Claire Danel, Arnaud Scherpereel, Sylvie Lantuejoul, Julien Mazières, Laurent Greillier, Clarisse Audigier-Valette, Emmanuel Bergot, Denis Moro-Sibilot, Olivier…

Pleural Mesothelioma: Pathogenesis, Diagnosis, Treatment, Prognosis, and Survival

October 2, 2025 | Comments Off on Pleural Mesothelioma: Pathogenesis, Diagnosis, Treatment, Prognosis, and Survival

MedComm 2025 September 1 [Link] Libo Zhang, Meijuan Huang Abstract Pleural mesothelioma (PM) presents significant challenges in clinical management, with current treatment options such as chemotherapy, anti-angiogenic therapies, and immunotherapies…

Co-Targeting BCL-xL with MCL-1 Induces Lethal Mitochondrial Dysfunction in Diffuse Mesothelioma

October 1, 2025 | Comments Off on Co-Targeting BCL-xL with MCL-1 Induces Lethal Mitochondrial Dysfunction in Diffuse Mesothelioma

Molecular Cancer Therapeutics 2025 September 5 [Link] Yuan Xu, Cristian G Medina, Deborah R Surman, Lacey E Dobrolecki, Monica Vilchis, Maheshwari Ramineni, Susan G Hilsenbeck, Yanming Li, Naren Li, Siqi…

Inhibition of YB-1 phosphorylation enhances cisplatin activity and disrupts cell division in pleural mesothelioma

September 30, 2025 | Comments Off on Inhibition of YB-1 phosphorylation enhances cisplatin activity and disrupts cell division in pleural mesothelioma

British Journal of Cancer 2025 September 4 [Link] Karin Schelch, Nadine Maach, Muhammad Hashim, Benjamin Zitta, Dominik Kirchhofer, Gerald Timelthaler, Anna Solta, Dominik Emminger, Verena Kopatz, Mir A Hoda, Walter…

Evaluation of SOX6 immunohistochemical expression as a diagnostic marker in the distinction of epithelioid mesothelioma from lung carcinomas

September 29, 2025 | Comments Off on Evaluation of SOX6 immunohistochemical expression as a diagnostic marker in the distinction of epithelioid mesothelioma from lung carcinomas

Annals of Diagnostic Pathology 2025 August 26 [Link] Fatma Samy Hafez, Safaa Mahmoud Mohamed Abdelkhalek, Shaimaa Abdelraouf Elgohary Abstract Epithelioid mesothelioma (EM) is a pleural malignancy whose many histopathologic patterns…

Efficacy of postoperative immunotherapy on MPM patients after CRS + HIPEC: A single-center retrospective study based on propensity score matching

September 26, 2025 | Comments Off on Efficacy of postoperative immunotherapy on MPM patients after CRS + HIPEC: A single-center retrospective study based on propensity score matching

International Journal of Cancer 2025 September 2 [Link] Xin-Li Liang, Yan-Dong Su, Yu-Bin Fu, Yang Yu, Xin-Bao Li, Zhong-He Ji, Ru Ma, Rui Yang, He-Liang Wu, Yu-Run Cui, Yan Li…

Successful Response to First-Line Carboplatin, Pemetrexed, and Bevacizumab for Peritoneal Mesothelioma: Two Case Reports

September 25, 2025 | Comments Off on Successful Response to First-Line Carboplatin, Pemetrexed, and Bevacizumab for Peritoneal Mesothelioma: Two Case Reports

Case Reports in Oncology 2025 January 30 [Link] Tomonobu Koizumi, Shintaro Kanda, Nodoka Sekiguchi, Takuro Noguchi, Sei-Ichiro Eda, Hiroto Kitahara Abstract Introduction: Peritoneal mesothelioma is an extremely rare malignancy of…

CDKN2A deletion is associated with immune desertification in diffuse pleural mesothelioma

September 24, 2025 | Comments Off on CDKN2A deletion is associated with immune desertification in diffuse pleural mesothelioma

Journal of Experimental & Clinical Cancer Research 2025 August 28 [Link] Federica Torricelli, Benedetta Donati, Veronica Manicardi, Mila Gugnoni, Francesca Reggiani, Gloria Manzotti, Pierluigi Di Chiaro, Cristian Ascione, Simonetta Piana,…

Categories